Samsung Bioepis Expand its Footprints with the Launch of Hadlima (biosimilar- adalimumab) in Australia and Canada
Shots:
- Samsung Bioepis in collaboration with Merck broadens its global reach by launching Hadlima in Australia for multiple autoimmune diseases
- With the launch in Australia- Samsung Bioepis’ adalimumab is now available in three markets: Europe- Canada- and Australia
- Hadlima is Samsung Bioepis’ third anti-TNF biosimilar launched in Australia- following the launch of Brenzys (etanercept) and Renflexis (infliximab). Hadlima will be available on the PBS from Apr 01- 2021
Ref: GlobeNewswire | Image: Samsung Bioepis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
